HIGHLIGHTS
- who: March and colleagues from the Zhejiang University, China have published the research work: Astragaloside IV alleviates 1- deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway, in the Journal: (JOURNAL)
- what: Methods: This study assessed the therapeutic effect of Astragaloside IV (AST) against 1-deoxySL-induced cytotoxicity in_vitro and in rats with CKD. For other data in the article, one-way ANOVA was used and p and amp;lt; 0.05 indicated the significance level. at 6, 12, 18 and 24 h after AST and/or doxSA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.